Feb 24 2015 Relmada Therapeutics Announces Filing of Clinical Trial Application in Canada for Novel Oral Formulations of Buprenorphine View
Jan 16 2015 Relmada Therapeutics to Present at 11th Annual Noble Financial Capital Markets Equity Conference View
Jan 13 2015 Relmada Therapeutics Reaches Midway Point in Dose Escalation for Phase One Study of Novel NMDA Receptor Antagonist d-Methadone View
Jan 06 2015 Relmada Therapeutics to Provide Corporate Update at 2015 Biotech Showcase™ in San Francisco View
Dec 22 2014 Relmada Therapeutics Doses First Cohort of Subjects in Human Clinical Trial of d-Methadone View
Dec 10 2014 Relmada Therapeutics Appoints Christine Silverstein as Director of Investor Relations View
